Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. ##STR00001## The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.

Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. ##STR00001## The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention provides compounds, compositions thereof, and methods of using the same.

This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I): ##STR00001##
where R.sup.1, R.sup.2, n.sub.1, n.sub.2, m.sub.1, and m.sub.2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II): ##STR00002##
and b) one or more fatty acid amide compounds having the Formula (III): ##STR00003##
where R.sup.1, R.sup.2, n.sub.1, and n.sub.2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I): ##STR00001##
where R.sup.1, R.sup.2, n.sub.1, n.sub.2, m.sub.1, and m.sub.2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II): ##STR00002##
and b) one or more fatty acid amide compounds having the Formula (III): ##STR00003##
where R.sup.1, R.sup.2, n.sub.1, and n.sub.2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

A compound of formula (I), ##STR00001##
wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

A compound of formula (I), ##STR00001##
wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.